Skip to content

A multicenter prospective clinical study for the treatment of spleen and kidney insufficiency metrorrhagia and metrostaxis with Lingnan Hemostatic Prescription Erren Decoction

A multicenter prospective clinical study for the treatment of spleen and kidney insufficiency metrorrhagia and metrostaxis with Lingnan Hemostatic Prescription Erren Decoction

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900026347
Enrollment
Unknown
Registered
2019-10-01
Start date
2019-11-01
Completion date
Unknown
Last updated
2019-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metrorrhagia and metrostaxis

Interventions

Sponsors

The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
13 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Between the ages of 13 and 55 years. 2. (1) suddenly a lot of violence under the vaginal bleeding; (2) blood dripping more than 14 days (in line with one of them). 3. (1) dark red or light red; (2) by thin (accord with one of them). 4. (1) weak waist and knees, chills and cold limbs, insomnia, tinnitus, and loss of libido; (2) loose stool, fatigue, poor diet, abnormal complexion (yellow or white) (at least in line with 1, 2 in each). 5. Tongue veins: the tongue is light and dark, with thin white coating and heavy and fine veins. 6. The subject voluntarily participates in the study and has signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Vaginal bleeding caused by pregnancy. 2. Organic lesions, such as genital malignant tumor, uterine fibroids, adenomyosis and other abnormal uterine bleeding. 3. Abnormal uterine bleeding caused by reproductive tract infection. 4. Bleeding of vulva, vagina and cervix. 5. Abnormal uterine bleeding caused by cardiovascular diseases, liver diseases, blood system diseases, etc. 6. Hemoglobin less than 90g/L.

Design outcomes

Primary

MeasureTime frame
The bleeding time;

Secondary

MeasureTime frame
Duration of hemostasis;TCM symptom score;Blood analysis;Four coagulation;

Countries

China

Contacts

Public ContactLing Zhu

Guangzhou University of Traditional Chinese Medicine

2275898821@qq.com+86 13570578779

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026